Spectrum Pharmaceuticals (SPPI) 11.79 -0.01

Spectrum Pharmaceuticals, Inc.
(SPPI) 11.79 -0.01

Last Trade:	11.79	Day Range:	11.50 - 11.81
Trade Time:	08:05PM	52wk Range:	6.9406 - 16.00
Prev. Close:	11.80	Market Cap:	701.77M
Open:	11.70	Div Yield:	0
Volume:	1196032	PE:	90
EPS:	1.31

The Latest On SPPI

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics 5/25/12 7:13am

Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination with the Redox Modulating Agent Motexafin Gadolinium 5/17/12 7:00am

Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics 5/10/12 7:04am

Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV 4/23/12 7:11am

Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index 4/19/12 7:24am

Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics at $1.82/Share for Each Allos Stock 4/16/12 8:15am

Benzinga's M&A Chatter for Thursday April 5, 2012 4/8/12 1:14pm

Spectrum Pharmaceuticals Down 9.6% on Negative Trial Data, Allos Therapeutics Acquisition 4/5/12 10:47am

Benzinga's Top Pre-Market Losers 4/5/12 8:34am

Benzinga's Top Pre-Market Gainers 4/5/12 8:22am

A Peek Into The Market Before The Trading Starts 4/5/12 7:27am

Financial Breakfast: Morning News Summary for April 5, 2012 4/5/12 7:26am

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics 5/25/12

Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination with the Redox Modulating Agent Motexafin Gadolinium 5/17/12

Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics 5/10/12

Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV 4/23/12

Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index 4/19/12

Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics at $1.82/Share for Each Allos Stock 4/16/12

Benzinga's M&A Chatter for Thursday April 5, 2012 4/8/12

Spectrum Pharmaceuticals Down 9.6% on Negative Trial Data, Allos Therapeutics Acquisition 4/5/12

Benzinga's Top Pre-Market Losers 4/5/12

Benzinga's Top Pre-Market Gainers 4/5/12

A Peek Into The Market Before The Trading Starts 4/5/12

Financial Breakfast: Morning News Summary for April 5, 2012 4/5/12

Benzinga's M&A Chatter for Thursday April 5, 2012 4/8/12

Financial Breakfast: Morning News Summary for April 5, 2012 4/5/12

Weekly Traders Homework: The First Sign Of Weakness In 2012 2/12/12

Weekly Homework: When Will Bonds Unravel? (w/ Economic Calendar & Stock Radar) 1/17/12

Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar) 1/2/12

Best Biotech Stocks of 2011 12/27/11

Benzinga's M&A Chatter for Friday December 9, 2011 12/9/11

Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs 11/22/11

Pharma/Biotech Stocks Reporting on Breast Cancer Treatments 9/23/11

Does Spectrum Pharmaceuticals Have a Bright Future? 9/23/11

Mad Money Lightning Round: Cramer Likes Acme Packet (HEK, OVTI, AAPL, NGD, GLD, CAT, SPPI, PG, APKT) 5/13/11

Negative Rumors About Spectrum Pharmaceuticals Circulate (SPPI) 4/29/11

Financial Breakfast: Morning News Summary for April 5, 2012 4/5/12

McNicoll, Lewis & Vlak Comments on Spectrum Pharmaceuticals Acquiring Rights to Zevalin 1/25/12

McNicoll Lewis Vlak Maintains Buy on Spectrum Pharmaceuticals After Positive Zevalin Reports 1/23/12

Auriga Raises Price Target on Spectrum Pharmaceuticals to $18 1/17/12

Rodman & Renshaw Maintains Market Outperform Rating on Spectrum Pharma 12/9/11

Spectrum Pharma Will Successfully Defend its Patent on Fusilev, Says Auriga 12/9/11

Rodman & Renshaw Reiterates Spectrum Pharmaceuticals Market Outperform, $12 PT 11/21/11

Auriga Raises PT on Spectrum Pharma to $15 11/21/11

McNicoll, Lewis & Vlak Maintains Spectrum Pharmaceuticals Buy, $20.50 PT 9/26/11

Rodman & Renshaw Reiterates Market Outperform on Spectrum Pharmaceuticals 9/21/11

Rodman & Renshaw Reiterates Outperform Rating on Spectrum Pharmaceuticals 6/22/11

Benzinga's Top Upgrades (AFFY, SPPI, ARAY, NSC) 3/11/11

Trade SPPI
NOW!

Partner Headlines

Roundtable Top Picks for the Week of May 14th - Roundtable Review 5/14/12

Allos Narrows Loss, Awaits Takeover - Analyst Blog 5/7/12

Spectrum: Allos Acquisition Means Huge Upside Potential 5/4/12

Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) 4/27/12

'Mad Money' Lightning Round: Allscripts Is All Wrong 4/27/12

Biotech Stock Mailbag: AVI, Aveo, Spectrum 4/27/12

Bad News for Allos - Analyst Blog 4/23/12

Monday's Top 10 Articles, Videos on TheStreet 4/9/12

Allos Eyed by Spectrum Pharma - Analyst Blog 4/9/12

Company News for April 9, 2012 - Corporate Summary 4/9/12

Press Releases

Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics 5/24/12 Business Wire

Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics 5/10/12 Business Wire

Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index 4/19/12 Business Wire

Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics 4/16/12 Business Wire

Critical Alerts For Goldman Sachs, Seagate Technology, Spectrum Pharmaceuticals, Dover, and Ericsson by Seven Summits Research 4/9/12 Newswire

Block & Leviton LLP Investigates Allos Therapeutics, Inc. for Possible Breaches of Fiduciary Duties for Its Proposed Merger with Spectrum Pharmaceuticals 4/5/12 Newswire

Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012 4/5/12 Business Wire

Spectrum Pharmaceuticals to Present at the 24th Annual ROTH Conference 3/12/12 Business Wire

Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011 3/1/12 Business Wire

Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences 2/24/12 Business Wire

Spectrum Pharmaceuticals Announces Date and Time for Its Fourth Quarter and Fiscal Year 2011 Financial Results Conference Call 2/23/12 Business Wire

Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference 2/7/12 Business Wire

Get the latest SPPI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Spectrum Pharmaceuticals, Inc. stock price.

Spectrum Pharmaceuticals, Inc. by YCharts

Spectrum Pharmaceuticals (SPPI) 11.79 -0.01

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On SPPI

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social